HPV genotype profile in a Norwegian cohort with ASC-US and LSIL cytology with three year cumulative risk of high grade cervical neoplasia

Gynecologic Oncology

Volumn 148, Issue 1, 2018, Pages 111-117

  Lie, A K ^a,b   Trope A ^c   Skare, G B ^c   Bjorge T ^c,d   Jonassen, C M ^b   Brusegard, K ^a   Lonnberg S ^c  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b Østfold Hospital Trust   (Norway)

^c CANCER REGISTRY OF NORWAY   (Norway)

^d UNIVERSITY OF BERGEN   (Norway)

Author keywords

Cumulative risk CIN3 +; HPV genotype profile; Secondary screening

Indexed keywords

ADULT; ARTICLE; ATYPICAL SQUAMOUS CELLS OF UNDETERMINED SIGNIFICANCE CYTOLOGY; CANCER REGISTRY; CANCER RISK; COHORT ANALYSIS; CYTOLOGY; DATA BASE; DIAGNOSTIC TEST; EMERGENCY HEALTH SERVICE; FEMALE; FOLLOW UP; GENOTYPE; HIGH GRADE CERVICAL NEOPLASIA; HISTOPATHOLOGY; HUMAN; HUMAN PAPILLOMAVIRUS TEST; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 31; HUMAN PAPILLOMAVIRUS TYPE 33; HUMAN PAPILLOMAVIRUS TYPE 35; HUMAN PAPILLOMAVIRUS TYPE 52; HUMAN PAPILLOMAVIRUS TYPE 58; HUMAN TISSUE; LOW GRADE SQUAMOUS INTRAEPITHELIAL LESION CYTOLOGY; MAJOR CLINICAL STUDY; MIXED INFECTION; NORWAY; NORWEGIAN (PEOPLE); OBSERVATIONAL STUDY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SQUAMOUS INTRAEPITHELIAL LESION OF THE CERVIX; UTERINE CERVIX CARCINOMA; VIRUS DETECTION; WART VIRUS; GENETICS; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTION; PATHOLOGY; UTERINE CERVIX CARCINOMA IN SITU; UTERINE CERVIX DYSPLASIA; UTERINE CERVIX TUMOR; VIROLOGY;

ADULT; ATYPICAL SQUAMOUS CELLS OF THE CERVIX; CERVICAL INTRAEPITHELIAL NEOPLASIA; COHORT STUDIES; FEMALE; HUMANS; NORWAY; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; SQUAMOUS INTRAEPITHELIAL LESIONS OF THE CERVIX; UTERINE CERVICAL NEOPLASMS;

EID: 85033575377     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2017.10.031     Document Type: Article

References (39)

1. Arbyn, M., Sasieni, P., Meijer, C.J., Clavel, C., Koliopoulos, G., Dillner, J., Chapter 9: clinical applications of HPV testing: a summary of meta-analyses. Vaccine 24:Suppl. 3 (2006), S78–S89.
2. Dillner, J., Primary human papillomavirus testing in organized cervical screening. Curr. Opin. Obstet. Gynecol. 25 (2013), 11–16.
3. Arbyn, M., Anttila, A., Jordan, J., Ronco, G., Schenck, U., Segnan, N., et al. European guidelines for quality assurance in cervical cancer screening. Second edition–summary document. Ann. Oncol. 21 (2010), 448–458.
4. Arbyn, M., Raifu, A.O., Weiderpass, E., Bray, F., Anttila, A., Trends of cervical cancer mortality in the member states of the European Union. Eur. J. Cancer 45 (2009), 2640–2648 (Oxford, England: 1990).
5. Nanda, K., McCrory, D.C., Myers, E.R., Bastian, L.A., Hasselblad, V., Hickey, J.D., et al. Accuracy of the Papanicolaou test in screening for and follow-up of cervical cytologic abnormalities: a systematic review. Ann. Intern. Med. 132 (2000), 810–819.
6. Ronco, G., Dillner, J., Elfstrom, K.M., Tunesi, S., Snijders, P.J., Arbyn, M., et al. Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four European randomised controlled trials. Lancet 383 (2014), 524–532.
7. Isidean, S.D., Mayrand, M.H., Ramanakumar, A.V., Gilbert, L., Reid, S.L., Rodrigues, I., et al. Human papillomavirus testing versus cytology in primary cervical cancer screening: end-of-study and extended follow-up results from the Canadian cervical cancer screening trial. Int. J. Cancer 139 (2016), 2456–2466.
8. Wright, T.C., Stoler, M.H., Behrens, C.M., Sharma, A., Zhang, G., Wright, T.L., Primary cervical cancer screening with human papillomavirus: end of study results from the ATHENA study using HPV as the first-line screening test. Gynecol. Oncol. 136 (2015), 189–197.
9. Schiffman, M., Solomon, D., Findings to date from the ASC-US-LSIL Triage Study (ALTS). Arch. Pathol. Lab. Med. 127 (2003), 946–949.
10. Arbyn, M., Buntinx, F., Van Ranst, M., Paraskevaidis, E., Martin-Hirsch, P., Dillner, J., Virologic versus cytologic triage of women with equivocal Pap smears: a meta-analysis of the accuracy to detect high-grade intraepithelial neoplasia. J. Natl. Cancer Inst. 96 (2004), 280–293.
11. Cuzick, J., Bergeron, C., von Knebel Doeberitz, M., Gravitt, P., Jeronimo, J., Lorincz, A.T., et al. New technologies and procedures for cervical cancer screening. Vaccine 30:Suppl. 5 (2012), F107–16.
12. Verdoodt, F., Szarewski, A., Halfon, P., Cuschieri, K., Arbyn, M., Triage of women with minor abnormal cervical cytology: meta-analysis of the accuracy of an assay targeting messenger ribonucleic acid of 5 high-risk human papillomavirus types. Cancer Cytopathol. 121 (2013), 675–687.
13. Bouvard, V., Baan, R., Straif, K., Grosse, Y., Secretan, B., El Ghissassi, F., et al. A review of human carcinogens–part B: biological agents. Lancet Oncol. 10 (2009), 321–322.
14. Haldorsen, T., Skare, G.B., Ursin, G., Bjorge, T., Results of delayed triage by HPV testing and cytology in the Norwegian Cervical Cancer Screening Programme. Acta Oncol., 2014, 1–10.
15. Nygård, M., Catch-HPV, What is Known About HPV-related Cancers in Norway, and How to Act? Cancer in Norway - Special Issue. Oslo. 2014.
16. Solomon, D., Davey, D., Kurman, R., Moriarty, A., O'Connor, D., Prey, M., et al. The 2001 Bethesda system: terminology for reporting results of cervical cytology. JAMA 287 (2002), 2114–2119.
17. Sotlar, K., Diemer, D., Dethleffs, A., Hack, Y., Stubner, A., Vollmer, N., et al. Detection and typing of human papillomavirus by e6 nested multiplex PCR. J. Clin. Microbiol. 42 (2004), 3176–3184.
18. Trope, A., Sjoborg, K.D., Nygard, M., Roysland, K., Campbell, S., Alfsen, G.C., et al. Cytology and human papillomavirus testing 6 to 12 months after ASC-US or LSIL cytology in organized screening to predict high-grade cervical neoplasia between screening rounds. J. Clin. Microbiol. 50 (2012), 1927–1935.
19. Dillner, L., Kemetli, L., Elfgren, K., Bogdanovic, G., Andersson, P., Carlsten-Thor, A., et al. Randomized health services study of human papillomavirus-based management of low-grade cytological abnormalities. Int. J. Cancer 129 (2011), 151–159.
20. Kelly, R.S., Patnick, J., Kitchener, H.C., Moss, S.M., HPV testing as a triage for borderline or mild dyskaryosis on cervical cytology: results from the Sentinel Sites study. Br. J. Cancer 105 (2011), 983–988.
21. A randomized trial on the management of low-grade squamous intraepithelial lesion cytology interpretations. Am. J. Obstet. Gynecol., 188, 2003, 1393–1400.
22. Results of a randomized trial on the management of cytology interpretations of atypical squamous cells of undetermined significance. Am. J. Obstet. Gynecol., 188, 2003, 1383–1392.
23. Sjoeborg, K.D., Trope, A., Lie, A.K., Jonassen, C.M., Steinbakk, M., Hansen, M., et al. HPV genotype distribution according to severity of cervical neoplasia. Gynecol. Oncol. 118 (2010), 29–34.
24. Guan, P., Howell-Jones, R., Li, N., Bruni, L., de Sanjose, S., Franceschi, S., et al. Human papillomavirus types in 115,789 HPV-positive women: a meta-analysis from cervical infection to cancer. Int. J. Cancer 131 (2012), 2349–2359.
25. Petry, K.U., Cox, J.T., Johnson, K., Quint, W., Ridder, R., Sideri, M., et al. Evaluating HPV-negative CIN2 + in the ATHENA trial. Int. J. Cancer 138 (2016), 2932–2939.
26. Rodriguez-Carunchio, L., Soveral, I., Steenbergen, R.D., Torne, A., Martinez, S., Fuste, P., et al. HPV-negative carcinoma of the uterine cervix: a distinct type of cervical cancer with poor prognosis. BJOG 122 (2015), 119–127.
27. Castle, P.E., Schiffman, M., Burk, R.D., Wacholder, S., Hildesheim, A., Herrero, R., et al. Restricted cross-reactivity of hybrid capture 2 with nononcogenic human papillomavirus types. Cancer Epidemiol. Biomark. Prev. 11 (2002), 1394–1399.
28. Poljak, M., Marin, I.J., Seme, K., Vince, A., Hybrid Capture II HPV test detects at least 15 human papillomavirus genotypes not included in its current high-risk probe cocktail. J. Clin. Virol. 25:Suppl. 3 (2002), S89–S97.
29. Lie, A.K., Risberg, B., Borge, B., Sandstad, B., Delabie, J., Rimala, R., et al. DNA-versus RNA-based methods for human papillomavirus detection in cervical neoplasia. Gynecol. Oncol. 97 (2005), 908–915.
30. Trope, A., Sjoborg, K., Eskild, A., Cuschieri, K., Eriksen, T., Thoresen, S., et al. Performance of human papillomavirus DNA and mRNA testing strategies for women with and without cervical neoplasia. J. Clin. Microbiol. 47 (2009), 2458–2464.
31. Schiffman, M., Vaughan, L.M., Raine-Bennett, T.R., Castle, P.E., Katki, H.A., Gage, J.C., et al. A study of HPV typing for the management of HPV-positive ASC-US cervical cytologic results. Gynecol. Oncol. 138 (2015), 573–578.
32. Schiffman, M., Hyun, N., Raine-Bennett, T.R., Katki, H., Fetterman, B., Gage, J.C., et al. A cohort study of cervical screening using partial HPV typing and cytology triage. Int. J. Cancer 139 (2016), 2606–2615.
33. Herrero, R., Hildesheim, A., Bratti, C., Sherman, M.E., Hutchinson, M., Morales, J., et al. Population-based study of human papillomavirus infection and cervical neoplasia in rural Costa Rica. J. Natl. Cancer Inst. 92 (2000), 464–474.
34. Persson, M., Elfstrom, K.M., Olsson, S.E., Dillner, J., Andersson, S., Minor cytological abnormalities and up to 7-year risk for subsequent high-grade lesions by HPV type. PLoS One, 10, 2015, e0127444.
35. Monsonego, J., Cox, J.T., Behrens, C., Sandri, M., Franco, E.L., Yap, P.S., et al. Prevalence of high-risk human papilloma virus genotypes and associated risk of cervical precancerous lesions in a large U.S. screening population: data from the ATHENA trial. Gynecol. Oncol. 137 (2015), 47–54.
36. Sjoeborg, K.D., Trope, A., Lie, A.K., Jonassen, C.M., Steinbakk, M., Hansen, M., et al. HPV genotype distribution according to severity of cervical neoplasia. Gynecol. Oncol. 118 (2010), 29–34.
37. Munoz, N., Castellsague, X., de Gonzalez, A.B., Gissmann, L., Chapter 1: HPV in the etiology of human cancer. Vaccine 24:S3 (2006), S1–S10.
38. Bjorge, T., Skare, G.B., Bjorge, L., Trope, A., Lonnberg, S., Adverse pregnancy outcomes after treatment for cervical intraepithelial neoplasia. Obstet. Gynecol. 128 (2016), 1265–1273.
39. Joura, E.A., Giuliano, A.R., Iversen, O.E., Bouchard, C., Mao, C., Mehlsen, J., et al. A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women. N. Engl. J. Med. 372 (2015), 711–723.